Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/29/2025

Preventing RSV Infection in Pregnancy

Vaccination Recommendations

  • The Centers for Disease Control and Prevention (CDC) recommends RSV vaccination for pregnant persons at 32-36 weeks' gestation during September-January in most of the continental United States 1, 4
  • Vaccination should be timed 1-2 months before the anticipated start of RSV season and continue through 2-3 months before the anticipated end of the season 1, 2
  • In regions with different RSV seasonality (Alaska, southern Florida, Guam, Hawaii, Puerto Rico, U.S.-affiliated Pacific Islands, and U.S. Virgin Islands), providers should follow local guidance on vaccination timing 1, 4
  • RSV vaccine can be administered simultaneously with other recommended vaccines for pregnant persons (Tdap, influenza, COVID-19) at different anatomic sites on the same day 1, 4

Effectiveness and Safety

  • Maternal RSV vaccination provides protection to infants during their most vulnerable period, though protection likely wanes after approximately 3 months 4, 5
  • At least 14 days are needed after maternal vaccination for development and transplacental transfer of maternal antibodies to protect the infant 4, 5
  • No statistically significant differences were observed between vaccine and placebo groups for preterm birth, low birthweight, or neonatal jaundice outcomes 2, 4
  • Current recommendations are for a single lifetime dose; no data are available on efficacy or safety of additional doses during subsequent pregnancies 1, 4

Alternative Protection: Nirsevimab for Infants

  • For infants whose mothers did not receive RSV vaccine during pregnancy, nirsevimab (a long-acting monoclonal antibody) is recommended for infants aged <8 months who are born during or entering their first RSV season 1, 4
  • Either maternal RSV vaccination or infant nirsevimab administration is recommended, but both are not needed for most infants 1, 4
  • Nirsevimab is recommended for all infants born at <34 weeks gestation, regardless of maternal vaccination status 4, 5

Additional Preventive Measures

  • Keep high-risk infants away from crowds and situations where exposure to infected people cannot be controlled 6, 7
  • Restrict participation in group child care during RSV season when feasible 6, 7
  • Practice careful hand hygiene 6, 7
  • Ensure all eligible infants and their contacts receive influenza vaccine and other age-appropriate immunizations 6, 7
  • Eliminate exposure to tobacco smoke 7